Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.59 EUR | +1.50% | +0.65% | -39.58% |
05-29 | European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading | MT |
05-28 | Solaria expects energy prices to rise this year | RE |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- With a P/E ratio at 12.83 for the current year and 8.52 for next year, earnings multiples are highly attractive compared with competitors.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-39.58% | 6.12B | - | ||
-2.29% | 89.87B | A- | ||
-3.95% | 37.57B | A- | ||
+63.05% | 26.47B | A | ||
-22.14% | 14.25B | C | ||
-7.96% | 12.99B | B- | ||
-9.33% | 11.93B | D+ | ||
-46.33% | 10.84B | B | ||
+5.77% | 9.11B | B+ | ||
-17.66% | 7.32B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GRF Stock
- 0RDV Stock
- Ratings Grifols, S.A.